Authors: Akkerhuis, KM van den Brand, MJBM van der Zwaan, C Peels, HOJ Suryapranata, H van der Wieken, LR Stibbe, J Hoffmann, J Baardman, T Deckers, JW Simoons, ML

Citation: Km. Akkerhuis et al., Pharmacodynamics and safety of lefradafiban, an oral platelet glycoproteinIIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty, HEART, 85(4), 2001, pp. 444-450

Authors: Ghuran, A van der Wieken, LR Nolan, J

Citation: A. Ghuran et al., Cardiovascular complications of recreational drugs - Are an important cause of morbidity and mortality, BR MED J, 323(7311), 2001, pp. 464-466

Authors: Ronner, E van Kesteren, HAM Zijnen, P Altmann, E Molhoek, PG van der Wieken, LR Cuffie-Jackson, CA Neuhaus, KL Simoons, ML

Citation: E. Ronner et al., Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction - A phase II dose escalation, randomized, double-blind study, EUR HEART J, 21(18), 2000, pp. 1530-1536

Authors: Ronner, E van der Wieken, LR Slagboom, TS Laarman, GJ Kiemeneij, F

Citation: E. Ronner et al., IIb/IIIa receptor antagonists for failed rescue angioplasty, CIRCULATION, 101(2), 2000, pp. 214-215